ClinicalTrials.gg
CompletedNCT02027753TEDUpdated Aug 27, 2015

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

A Phase 4 interventional study of INSULIN GLARGINE and Metformin in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
109
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
119th of 175
109 · median 253
Started
2013
with 7 others
Phase 4
103 of 176
2 open now
Registered
109th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 119th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2013, is one of 103 in phase 4, and was the 109th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea

Secondary Objectives:

  1. To assess the efficacy by adding insulin glargine
  2. To assess insulin dose
  3. Safety
Read the detailed description

28 weeks (Screening: About 2 weeks/Treatment: 24 weeks (6 months)/Follow-up: 2 weeks)

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 Diabetes mellitus ≥ 20 aged
  • Patients who are treated with DPP- 4 for at least 3 months before with metformin plus or minus sulphonylurea inadequately controlled with ≥ 7.5%
  • Be able and voluntarily agree to participate in this study by signing a written informed consent

Exclusion criteria

Exclusion criteria:

  • Diabetes patients other than Type 2 (eg. Type 1 Diabetes mellitus, pancreatic disease, secondary diabetes)
  • > 11% at screening
  • History of continuous basal insulin treatment within 1 year before screening
  • History of diabetic acidosis (including keto-acidosis) within 1 year before screening
  • History of myocardial infarct, stroke or heart failure related admission within 3 months before screening
  • History of drug or alcoholic abuse within 6 months before screening
  • Weight change ≥ 5 kg within 3 months before screening
  • History of hypoglycemic unawareness
  • Systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg regardless of taking anti-hypertensive, or uncontrolled hypertension
  • Active malignant cancer, major systemic disease, diabetic retinopathy, macular edema necessitating laser treatment, abnormal clinical finding from physical examination, lab analysis, or vital sign, which can be regarded as to prevent safe completion of clinical study or to make efficacy assessment difficult by investigator or co-investigator at screening
  • Pregnant or lactating women
  • Women of child bearing potential (Pre-menopause or not surgically infertile within 3 months before screening) who match two conditions below:
  • Negative serum pregnancy test at screening
  • Using medically proven effective method
  • to drugs
  • Lab finding at screening:
  • Abnormal liver function: or Alkaline phosphatase > 3 times of
  • Renal insufficiency: Men with serum Cr ≥ 1.5 mg/dL (≥ 133µmol/L), women with serum Cr ≥ 1.4 mg/dL (≥ 124 µmol/L)
  • Use of anti-obese drug within 3 months before screening
  • Has been using drugs that can influence glucose metabolism (systemic , thyroid hormone) within 3 months before screening or has possibility of using these drug during the investigational period
  • Has participated in clinical studies of any investigational drugs within 3 months before screening
  • Considered not physically or psychologically appropriate to participate in clinical study by investigator
  • Not willing to comply with scheduled visit, self-inject insulin, or self-monitor blood glucose level

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Insulin glargine and Oral anti diabetic treatment(s)

    1. Insulin glargine: Lantus * Add basal insulin: starting with 0.2 U/kg/day or 10 U/day * Adjust insulin glargine dose according to Fasting blood glucose 2. Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion.

    Drug: INSULIN GLARGINE · Drug: Metformin · Drug: DPP-4 inhibitor · Drug: Sulphonylurea

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • DrugSulphonylurea

    Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy

    Time frame: week 24 (6 months)

Secondary outcomes

  1. Percentage of patients with HbA1c ≤7%

    Time frame: week 12 (3 months)

  2. Change from baseline in HbA1c

    Time frame: week 12 (3 months), week 24 (6 months)

  3. Percentage of patients with HbA1c ≤6.5%

    Time frame: week 12 (3 months), week 24 (6 months)

  4. Change from baseline in Fasting Plasma glucose (FPG), 2hr-Postprandial Plasma Glucose

    Time frame: week 12 (3 months), week 24 (6 months)

  5. Total daily insulin dose

    Time frame: week 24 (6 months)

  6. Fasting blood glucose (FBG) values

    Time frame: During 3 consecutive days before baseline, week 12, Week 24

  7. 7-point Self Monitoring of Blood Glucose

    Time frame: During 2 days within 7 days before baseline, week 12, week 24

  8. Weight change from baseline

    Time frame: week 24 (6 months)

  9. Number of Patients with Hypoglycemic Events

    Time frame: up to 6 months

  10. Number of Patients with Adverse Events

    Time frame: up to 6 months

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2014
First posted
Jan 6, 2014
Start
Dec 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02027753
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 6, 2014
Start date
Dec 2013
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Aug 27, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Metformin · DPP-4 inhibitors

Start the discussion